Skip to main content
Table of Contents
Print

What Is NICE’s Position on Cannabis for Anxiety Disorders? 

Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

The National Institute for Health and Care Excellence (NICE) provides guidance to clinicians on evidence-based treatments in the UK. NICE’s cannabis for anxiety  guidance evaluates the current evidence and outlines the organisation’s approach to medical cannabis use. Understanding UK guidelines, policy stance, and clinical recommendations helps patients and healthcare providers navigate cannabis as a potential option for anxiety management. 

Key Points from NICE Guidance 

Reviewing NICE cannabis for anxiety guidance clarifies the regulatory and clinical context in the UK. 

UK Guidelines 

UK guidelines emphasise that cannabis should generally not be used for anxiety disorders outside of clinical trials due to limited high-quality evidence supporting its efficacy. 

Policy Stance 

The policy stance of NICE is cautious, highlighting potential risks, the need for more rigorous studies, and recommending established treatments as first-line therapy. 

Clinical Recommendations 

Clinical recommendations focus on prioritising evidence-based therapies such as cognitive behavioural therapy and pharmacological interventions while considering cannabis only under strict clinical oversight or research settings. 

Personalised Approach 

Clinicians can use NICE’s cannabis for anxiety guidance to inform conversations with patients, balancing potential benefits against regulatory restrictions and individual clinical needs. 

By understanding NICE’s cannabis for anxiety guidance, including UK guidelines, policy stance, and clinical recommendations, patients and providers can make informed decisions. While cannabis may hold potential, NICE currently supports cautious, evidence-based use primarily within research or specialist contexts, ensuring safety and appropriate management of anxiety disorders. 

If you’re exploring cannabis treatment options for anxiety disorders, visit providers like LeafEase for personalised consultations and guidance tailored to your needs. 

For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to Medical Cannabis and anxiety disorders. 

Julia Sutton, MSc
Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy. 

Dr. Clarissa Morton, PharmD
Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy. 

Categories